Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Epilepsy treatment lacks therapies targeting epileptogenesis, the process leading to unprovoked seizures.
• Tuberous Sclerosis Complex (TSC), a genetic disorder, is frequently associated with epilepsy.
• The mechanistic/mammalian target of rapamycin (mTOR) pathway is implicated in TSC and epilepsy development.

Purpose of the Study:

• To explore the potential of targeting the mTOR pathway for novel antiepileptogenic therapies.
• To address the unmet need for treatments preventing seizure onset or progression.

Main Methods:

• Review of existing research on the mTOR pathway in animal models of epilepsy.
• Analysis of downstream effectors of the mTOR pathway in relation to seizure generation mechanisms.

Main Results:

• Evidence suggests mTOR pathway downstream effectors contribute to seizure generation.
• The mTOR pathway is a promising target for antiepileptogenic interventions.

Conclusions:

• The mTOR pathway presents a rational target for developing new therapies to prevent epilepsy.
• Targeting mTOR may offer a novel strategy for managing epilepsy in TSC and other conditions.